Fig. 6

PF-06747143 inhibits CXCL12-induced tumor cell actin polymerization and migration. a B-CLL patient cells were treated with no compound (negative control), AMD3100 (4 and 40 μM), or PF-06747143 (10, 100, and 1000 nM) prior to stimulation with CXCL12 (90 nM) for 15 s. F-actin polymerization was measured using FITC-labeled phalloidin in CD19/CD5-pre-labeled CLL patient cells. All samples are plotted relative to the mean fluorescence intensity of the negative control group, without chemokine CXCL12, set to 100%. The results of samples analyzed in duplicates with the mean ± SD are shown for each group. b CLL patient primary cells were incubated with PF-06747143 (10, 100, 1000 nM) or AMD3100 (4 and 40 μM) for 1 h and loaded onto a transwell chamber and incubated for 2 h in the presence of CXCL12 (12 nM) or media control. Cells that migrated to the lower chamber were enumerated using flow cytometry. The results of samples analyzed in duplicates with the mean ± SD are shown for each group. Statistical significance was determined using Bonferroni’s correction test